切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2015, Vol. 09 ›› Issue (01) : 5 -7. doi: 10.3877/cma. j. issn.1674-0807.2015.01.002

专家论坛

2014年圣安东尼奥乳腺癌研讨会回顾
邵志敏1,(), 郑以孜1   
  1. 1.200032 上海,复旦大学附属肿瘤医院乳腺外科
  • 收稿日期:2014-12-30 出版日期:2015-02-01
  • 通信作者: 邵志敏

Review of 2014 San Antonio Breast Cancer Symposium

Zhimin Shao(), Yizi Zheng   

  • Received:2014-12-30 Published:2015-02-01
  • Corresponding author: Zhimin Shao
引用本文:

邵志敏, 郑以孜. 2014年圣安东尼奥乳腺癌研讨会回顾[J/OL]. 中华乳腺病杂志(电子版), 2015, 09(01): 5-7.

Zhimin Shao, Yizi Zheng. Review of 2014 San Antonio Breast Cancer Symposium[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(01): 5-7.

[1]
Francis PA, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer(BC): Analysis of the SOFT trial[EB/OL]. [2014-12-11].http: / /www. abstracts2view. com/sabcs14/view. php? nu =SABCS13L_146&terms=.
[2]
Pagani O,Regan MM, Walley BA,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer [J].N Engl J Med,2014,371(2): 107-118.
[3]
Krop I, Johnston S, Mayer IA, et al. The FERGI phase II study of the PI3K inhibitor pictilisib ( GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+,aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer -Part I results[EB/OL]. [2014-12-10]. http: / /www.abstracts2view. com/sabcs14/view. php? nu = SABCS13L _248&terms=.
[4]
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med,2012,366(6): 520-529.
[5]
Hurvitz SA, Andre F, Jiang Z, et al. Phase 3, randomized,double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 + advanced breast cancer: BOLERO-1[EB/OL].[2014-12-12].http: / /www.abstracts2v iew.com/sabcs14/view.php? nu=SABCS13L_859&terms=.
[6]
Perez EA, Ballman KV, Anderson SK, et al. Stromal tumorinfiltrating lymphocytes(S-TILs): In the alliance N9831 trial STILs are associated with chemotherapy benefit but not associated with trastuzumab benefit[EB/OL]. [2014-12-12]. http: / /www.abstracts2view.com/sabcs14/view.php? nu=SABCS13L_1455&terms=.
[7]
Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing[J]. Breast Cancer Res Treat,2014,145(3): 707-714.
[8]
Tutt A, Ellis P,Kilburn L,et al. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D)for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)[EB/OL]. [2014-12-11]. http: / /www. abstracts2view. com/sabcs14/view.php? nu=SABCS13L_789&terms=.
[9]
Nanda R, Chow LQ, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triplenegative breast cancer [EB/OL]. [2014-12-10]. http: / /www.abstracts2view.com/sabcs14/view.php? nu=SABCS13L_1349&terms=.
[1] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[2] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[3] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[7] 薛庆, 施赛叶, 徐雅文, 盛夏, 张芹芹. 追踪方法学联合失效模式与效应分析在膀胱灌注化疗患者中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 553-559.
[8] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[9] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[10] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[11] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[12] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[13] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[14] 张颖, 赵鑫, 陈佳梅, 李雁. 术前化疗对CRS+HIPEC 治疗腹膜假黏液瘤预后影响的meta 分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 826-835.
[15] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
阅读次数
全文


摘要